Woodford and Threadneedle most exposed to AstraZeneca

Ketan Patel, fund manager at EdenTree Investment Management, tells Fund Strategy that AstraZeneca shareholders “will need strong stomachs” if they are to keep investing in the pharmaceutical giant. He explains that despite having a 5% yield, the almost unprecedented share drop of 15.9% is worrying.